Apalset, Ellen M.
Lunde, Astrid http://orcid.org/0000-0001-7246-9199
Hoff, Mari
Ehrenstein, Vera
Tell, Grethe S.
Funding for this research was provided by:
University of Bergen
Article History
Received: 9 February 2020
Accepted: 1 July 2020
First Online: 5 August 2020
Compliance with ethical standards
:
: Astrid Lunde is involved in the Denosumab Global Safety Study (Amgen protocol 20090522; Amgen Inc., Thousand Oaks). Department of Clinical Epidemiology, Aarhus University receives an institutional research funding from several pharmaceutical companies, some of which manufacture AOD. None of these companies was involved in the current study. Vera Ehrenstein is a salaried employee of the Aarhus University. Ellen M. Apalset, Mari Hoff, and Grethe S. Tell declare that they have no conflict of interest.
: Data from the Denosumab Global Safety Study was used in this study, with approval from the Norwegian Data Protection Agency (ref. 11/00192-5) and from the ethics committee (ref. 2010/2616-2).
: “Data from the Norwegian Patient Register have been used in this publication. The interpretation and reporting of these data are the sole responsibility of the authors, and no endorsement by the Norwegian Patient Register is intended nor should be inferred.”